/PRNewswire/ The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered.
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
02.12.2021 - – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to be confirmed by further in vitro pseudo-virus .
GSK - GlaxoSmithKline plc (via Public) / Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.